MorphoSys AG (ETR:MOR) shares hit a new 52-week high during mid-day trading on Wednesday . The stock traded as high as €114.70 ($133.37) and last traded at €114.40 ($133.02), with a volume of 86915 shares traded. The stock had previously closed at €111.30 ($129.42).
A number of brokerages recently weighed in on MOR. Berenberg Bank set a €145.00 ($168.60) price objective on shares of MorphoSys and gave the company a “buy” rating in a report on Tuesday, November 19th. Independent Research set a €110.00 ($127.91) target price on shares of MorphoSys and gave the stock a “neutral” rating in a research note on Friday, November 1st. JPMorgan Chase & Co. set a €130.00 ($151.16) target price on shares of MorphoSys and gave the stock a “buy” rating in a report on Monday, November 18th. Royal Bank of Canada set a €130.00 ($151.16) price target on shares of MorphoSys and gave the company a “buy” rating in a research report on Tuesday, November 19th. Finally, Goldman Sachs Group set a €114.00 ($132.56) price target on shares of MorphoSys and gave the stock a “neutral” rating in a research note on Tuesday, November 19th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the stock. MorphoSys has a consensus rating of “Hold” and an average target price of €119.86 ($139.37).
The company has a debt-to-equity ratio of 9.78, a quick ratio of 7.63 and a current ratio of 7.80. The company has a market cap of $3.62 billion and a price-to-earnings ratio of -37.61. The business has a 50-day simple moving average of €101.84 and a 200-day simple moving average of €98.76.
MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 115 drugs for various diseases, such as psoriasis, Alzheimer's diseases, haematological malignancies, solid tumors, hemophilia, multiple myeloma, metabolic diseases, inflamation, thrombosis, brittle bone syndrome, eye diseases, cancers, diabetic eye diseases, blood disorders, and asthma.
Featured Article: Rule of 72
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.